Related Experiment Video
Updated: Apr 26, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition
1Forum for Collaborative HIV Research, School of Public Health, University of California, Berkeley, California, USA.
Abstract:
Antiretrovirals (ARVs) decrease the infectiousness of treated HIV-infected persons and can reduce the acquisition of HIV infection when taken by uninfected persons. Coformulated emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is approved in the United States for the preexposure prophylaxis (PrEP) indication, changing the regulatory landscape for new prophylactic agents. We describe the challenge of conducting rigorous clinical end-point trials for prophylactic agents and point to alternatives that leverage new information about correlates of HIV risk and protection.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Retroviruses

